Insmed (NASDAQ:INSM) Coverage Initiated by Analysts at Jefferies Financial Group

Research analysts at Jefferies Financial Group initiated coverage on shares of Insmed (NASDAQ:INSM) in a research note issued on Monday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Several other brokerages have also commented on INSM. Roth Mkm upgraded Insmed to a “strong-buy” rating in a research note on Friday, January 23rd. TD Cowen set a $241.00 target price on shares of Insmed in a research report on Thursday, December 18th. Stifel Nicolaus set a $205.00 price target on shares of Insmed in a research report on Thursday, February 19th. Barclays assumed coverage on shares of Insmed in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 price objective for the company. Finally, UBS Group cut their target price on shares of Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, January 6th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $207.52.

Insmed Trading Up 2.7%

INSM traded up $3.81 during midday trading on Monday, hitting $143.31. The company’s stock had a trading volume of 442,094 shares, compared to its average volume of 2,410,482. Insmed has a 52-week low of $60.40 and a 52-week high of $212.75. The firm has a 50-day moving average price of $155.18 and a two-hundred day moving average price of $166.16. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The firm has a market cap of $30.89 billion, a P/E ratio of -22.38 and a beta of 1.13.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same period in the prior year, the business posted ($1.32) earnings per share. Insmed’s revenue was up 152.6% on a year-over-year basis. On average, research analysts anticipate that Insmed will post -4.56 earnings per share for the current year.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 10,699 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $146.03, for a total transaction of $1,562,374.97. Following the sale, the chief executive officer owned 301,185 shares in the company, valued at $43,982,045.55. This represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sara Bonstein sold 748 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total value of $116,942.32. Following the transaction, the chief financial officer directly owned 79,758 shares of the company’s stock, valued at $12,469,365.72. This trade represents a 0.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 189,651 shares of company stock valued at $31,784,545 over the last three months. 3.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Insmed by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after buying an additional 1,140,524 shares during the period. Darwin Global Management Ltd. grew its position in shares of Insmed by 2.3% during the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after acquiring an additional 475,832 shares during the last quarter. Capital International Investors grew its position in shares of Insmed by 1.0% during the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after acquiring an additional 74,994 shares during the last quarter. State Street Corp increased its holdings in shares of Insmed by 30.6% in the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after acquiring an additional 1,217,390 shares during the period. Finally, Artisan Partners Limited Partnership increased its holdings in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares during the period.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.